TXNDC17 Promotes Paclitaxel Resistance Via Inducing Autophagy in Ovarian Cancer

Overview

Journal Autophagy

Specialty Cell Biology

Date 2015 Jan 22

PMID 25607466

Citations 95

Authors

Song-Fa Zhang

Xin-Yu Wang

Zhi-Qin Fu

Qiao-Hua Peng

Jian-Yang Zhang

Feng Ye

Yun-Feng Fu

Cai-Yun Zhou

Wei-Guo Lu

Xiao-Dong Cheng

Xing Xie

Affiliations

Soon will be listed here.

Abstract

Paclitaxel is recommended as a first-line chemotherapeutic agent against ovarian cancer, but drug resistance becomes a major limitation of its success clinically. The key molecule or mechanism associated with paclitaxel resistance in ovarian cancer still remains unclear. Here, we showed that TXNDC17 screened from 356 differentially expressed proteins by LC-MS/MS label-free quantitative proteomics was more highly expressed in paclitaxel-resistant ovarian cancer cells and tissues, and the high expression of TXNDC17 was associated with poorer prognostic factors and exhibited shortened survival in 157 ovarian cancer patients. Moreover, paclitaxel exposure induced upregulation of TXNDC17 and BECN1 expression, increase of autophagosome formation, and autophagic flux that conferred cytoprotection for ovarian cancer cells from paclitaxel. TXNDC17 inhibition by siRNA or enforced overexpression by a pcDNA3.1(+)-TXNDC17 plasmid correspondingly decreased or increased the autophagy response and paclitaxel resistance. Additionally, the downregulation of BECN1 by siRNA attenuated the activation of autophagy and cytoprotection from paclitaxel induced by TXNDC17 overexpression in ovarian cancer cells. Thus, our findings suggest that TXNDC17, through participation of BECN1, induces autophagy and consequently results in paclitaxel resistance in ovarian cancer. TXNDC17 may be a potential predictor or target in ovarian cancer therapeutics.

Citing Articles

Targeting autophagy in platinum-sensitive relapsed ovarian cancer: randomized phase II trial of hydroxychloroquine with chemotherapy with biomarker correlation.

Goenka L, Dubashi B, Kayal S, Rajappa M, Manivannan P, Chakkalakkoombil S Discov Oncol. 2025; 16(1):203.

PMID: 39969689 PMC: 11839959. DOI: 10.1007/s12672-025-01904-w.

Hui H, Zhou F, Pei S, Zhou W, Shang J, Wang P Sci Rep. 2025; 15(1):5246.

PMID: 39939413 PMC: 11822014. DOI: 10.1038/s41598-025-89908-y.

Mechanism of microRNA-152-3p-Mediated Regulation of Autophagy and Sensitivity in Paclitaxel-Resistant Ovarian Cancer Cells.

Wu D, Zhang Y, Zhang L, Xia W, Cai B, Dong F Onco Targets Ther. 2025; 18:179-197.

PMID: 39926373 PMC: 11806707. DOI: 10.2147/OTT.S485100.

KAT2B inhibits proliferation and invasion via inactivating TGF-β/Smad3 pathway-medicated autophagy and EMT in epithelial ovarian cancer.

Yao Y, Niu Y, Zhou H, Yong M Sci Rep. 2025; 15(1):3417.

PMID: 39870682 PMC: 11772695. DOI: 10.1038/s41598-024-83977-1.

LOC730101 improves ovarian cancer drug sensitivity by inhibiting autophagy-mediated DNA damage repair via BECN1.

Zhong Y, Shuai Y, Yang J, Zhang M, He T, Zheng L Cell Death Dis. 2024; 15(12):893.

PMID: 39695078 PMC: 11655529. DOI: 10.1038/s41419-024-07278-1.

References

Gorka M, Daniewski W, Gajkowska B, Lusakowska E, Godlewski M, Motyl T . Autophagy is the dominant type of programmed cell death in breast cancer MCF-7 cells exposed to AGS 115 and EFDAC, new sesquiterpene analogs of paclitaxel. Anticancer Drugs. 2005; 16(7):777-88. DOI: 10.1097/01.cad.0000171514.50310.85. View

Kanzawa T, Zhang L, Xiao L, Germano I, Kondo Y, Kondo S . Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene. 2004; 24(6):980-91. DOI: 10.1038/sj.onc.1208095. View

Jeong W, Jung Y, Kim H, Park S, Rhee S . Thioredoxin-related protein 14, a new member of the thioredoxin family with disulfide reductase activity: implication in the redox regulation of TNF-alpha signaling. Free Radic Biol Med. 2009; 47(9):1294-303. DOI: 10.1016/j.freeradbiomed.2009.07.021. View

Copetti T, Bertoli C, Dalla E, Demarchi F, Schneider C . p65/RelA modulates BECN1 transcription and autophagy. Mol Cell Biol. 2009; 29(10):2594-608. PMC: 2682036. DOI: 10.1128/MCB.01396-08. View

Orr G, Verdier-Pinard P, McDaid H, Horwitz S . Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003; 22(47):7280-95. PMC: 4039039. DOI: 10.1038/sj.onc.1206934. View

Turcotte S, Chan D, Sutphin P, Hay M, Denny W, Giaccia A . A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell. 2008; 14(1):90-102. PMC: 2819422. DOI: 10.1016/j.ccr.2008.06.004. View

Chen N, Karantza V . Autophagy as a therapeutic target in cancer. Cancer Biol Ther. 2011; 11(2):157-68. PMC: 3230307. DOI: 10.4161/cbt.11.2.14622. View

Katayama M, Kawaguchi T, Berger M, Pieper R . DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ. 2006; 14(3):548-58. DOI: 10.1038/sj.cdd.4402030. View

Bhalla K . Microtubule-targeted anticancer agents and apoptosis. Oncogene. 2003; 22(56):9075-86. DOI: 10.1038/sj.onc.1207233. View

10.

Li Y, Ye F, Cheng X, Hu Y, Zhou C, Lu W . Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer. Eur J Cancer. 2010; 46(11):2104-18. DOI: 10.1016/j.ejca.2010.04.015. View

11.

Li B, Li C, Peng R, Wu X, Wang H, Wan D . The expression of beclin 1 is associated with favorable prognosis in stage IIIB colon cancers. Autophagy. 2008; 5(3):303-6. DOI: 10.4161/auto.5.3.7491. View

12.

Yang Z, Chee C, Huang S, Sinicrope F . The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther. 2011; 10(9):1533-41. PMC: 3170456. DOI: 10.1158/1535-7163.MCT-11-0047. View

13.

Lin H, Qiu H, Zeng F, Rao H, Yang G, Kung H . Decreased expression of Beclin 1 correlates closely with Bcl-xL expression and poor prognosis of ovarian carcinoma. PLoS One. 2013; 8(4):e60516. PMC: 3616009. DOI: 10.1371/journal.pone.0060516. View

14.

Di Michele M, Corte A, Cicchillitti L, Del Boccio P, Urbani A, Ferlini C . A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines. Biochim Biophys Acta. 2008; 1794(2):225-36. DOI: 10.1016/j.bbapap.2008.09.017. View

15.

Carew J, Nawrocki S, Kahue C, Zhang H, Yang C, Chung L . Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood. 2007; 110(1):313-22. PMC: 1896119. DOI: 10.1182/blood-2006-10-050260. View

16.

Fu Y, Ye D, Chen H, Lu W, Ye F, Xie X . Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30. Gynecol Oncol. 2007; 105(1):66-73. DOI: 10.1016/j.ygyno.2006.10.061. View

17.

Harris J . Autophagy and cytokines. Cytokine. 2011; 56(2):140-4. DOI: 10.1016/j.cyto.2011.08.022. View

18.

Wirawan E, Lippens S, Vanden Berghe T, Romagnoli A, Fimia G, Piacentini M . Beclin1: a role in membrane dynamics and beyond. Autophagy. 2011; 8(1):6-17. DOI: 10.4161/auto.8.1.16645. View

19.

Morgan Jr R, Alvarez R, Armstrong D, Burger R, Castells M, Chen L . Ovarian cancer, version 3.2012. J Natl Compr Canc Netw. 2012; 10(11):1339-49. DOI: 10.6004/jnccn.2012.0140. View

20.

Veldhoen R, Banman S, Hemmerling D, Odsen R, Simmen T, Simmonds A . The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis. Oncogene. 2012; 32(6):736-46. DOI: 10.1038/onc.2012.92. View